Juswinder Singh, CSO at Avila to speak at Drug Design Medicinal Chemistry Meeting Oct 19 2011, Cali

Aug. 16, 2011 - PRLog -- Juswinder Singh, Co-Founder and Chief Scientific Officer at Avila Therapeutics, will give a presentation on “The Resurgence of Covalent Drugs” at the 5th Drug Design and Medicinal Chemistry Conference to be held in San Diego, CA on October 19-21, 2011 by GTC.

Covalent drugs have proven to be successful therapies for a wide variety of indications, and yet are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the disconnect between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. Dr. Singh’s presentation surveys the prevalence and pharmacologic features of FDA approved covalent drugs and describes specific examples of a new generation of rationally engineered covalent drugs and their potential in the treatment of cancer and infectious disease.

The 5th Drug Design and Medicinal Chemistry Conference will discuss strategies for hit and target identification, fragment based drug design, chemoinformatics, protein-protein interactions, ligand based drug design, computer aided drug design, protein flexibility, high performance computing, covalent inhibitors, mutational resistance, selectivity of kinase inhibitors, potency, specificity, lead optimization, ADMET, safety in drug discovery, advances in drug delivery and much more.

This conference is part of the 7th Modern Drug Discovery & Development Summit, which includes three other concurrent tracks: 5th Biomarker Discovery & Development, 5th Advances in Stem Cell Discovery & Development and 4th Protein Discovery & Therapeutics.

Wednesday, October 19 will be dedicated to a Plenary Keynote session. Thursday, October 20 and Friday, October 21 will be dedicated to the four individual conference tracks of the summit.

For more information, please visit www.gtcbio.com